Journal
JOURNAL OF CARDIAC FAILURE
Volume 29, Issue 1, Pages 76-86Publisher
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
DOI: 10.1016/j.cardfail.2022.08.008
Keywords
Cardiac amyloidosis; atrial fibrillation; thromboembolic risk; anticoagulation
Categories
Ask authors/readers for more resources
Cardiac amyloidosis (CA) is characterized by the deposition of amyloid fibrils derived from misfolding of transthyretin (ATTR) or light-chain (AL) proteins in the myocardium, leading to atrial fibrillation and thromboembolism. It also increases the risk of bleeding. This review explores the prevalence, pathophysiological mechanisms, bleeding risk, and anticoagulation strategies in CA, aiming to identify knowledge gaps for future research on thromboembolism in CA.
Cardiac amyloidosis (CA) is caused by extracellular myocardial deposition of amyloid fibrils that are primary derived either from misfolding of transthyretin (ATTR) or light-chain (AL) proteins. CA is associated with atrial fibrillation, potentiated by electromechanical changes as a result of amyloid infiltration in the myocardium. CA also predisposes to thromboembolism and could potentially simultaneously elevate bleeding risk. In this review, we aim to explore and compare the prevalence and pathophysiological mechanisms of atrial fibrillation and thromboembolism in ATTR and AL, examine bleeding risk and factors that promote bleeding, and compare anticoagulation strategies in CA. Finally, we highlight knowledge gaps in the field of thromboembolism in CA to guide future research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available